Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/106531
Title: | Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia | Authors: | Stuckey, Ruth López-Rodríguez, Juan Francisco Sánchez Sosa, José Santiago Segura Díaz, Adrian Sánchez-Farías, Nuria Bilbao Sieyro, Cristina Gómez Casares, María Teresa |
UNESCO Clasification: | 32 Ciencias médicas 320101 Oncología |
Keywords: | BCR-ABL positive Biomarkers Chronic Duration of therapy Leukemia, et al |
Issue Date: | 2020 | Journal: | World Journal of Clinical Oncology | Abstract: | Clinical trials have demonstrated that some patients with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) who have maintained a molecular response can successfully discontinue treatment without relapsing. Treatment free remission (TFR) can be reached by approximately 50% of patients who discontinue. Despite having similar levels of deep molecular response and an identical duration of treatment, the factors that influence the successful discontinuation of CML patients remain to be determined. In this review we will explore the factors identified to date that can help predict whether a patient will successfully achieve TFR. We will also discuss the need for the identification of predictive biomarkers associated with a high probability of achieving TFR for the future personalized identification of patients who are suitable for the discontinuation of TKI treatment. | URI: | http://hdl.handle.net/10553/106531 | ISSN: | 2218-4333 | DOI: | 10.5306/wjco.v11.i12.996 | Source: | World Journal of Clinical Oncology [ISSN 2218-4333], v. 11 (12), p. 996-1007 (Diciembre 2020) |
Appears in Collections: | Artículos |
WEB OF SCIENCETM
Citations
6
checked on Oct 6, 2024
Page view(s)
107
checked on Jan 7, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.